Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The FDA has accepted Tranzyme Pharma's investigational new drug application for TZP-102 for the treatment of gastroparesis.
Subscribe to our email newsletter
TZP-102 is a second generation prokinetic drug that Tranzyme intends to develop for the treatment of mild-to-moderate gastroparesis and other chronic gastrointestinal motility disorders. A Phase I safety and tolerability trial of TZP-102 will begin immediately.
Vipin Garg, president and CEO of Tranzyme, said: “Advancing TZP-102 into clinical development further strengthens our product pipeline. Acceptance of this IND by the FDA represents a significant milestone for Tranzyme as well as for the technology underlying the discovery and development of this product.”